Key Highlights
- USD 200 million is the gross size of the offering priced by Recursion (NASDAQ:RXRX) on October 15, 2026: 61,540,000 Class A shares at USD 3.25, per the 8-K. The stock fell 8.18% to USD 3.82 on October 16, per published market data.
- 29.50% of the float in Recursion (NASDAQ:RXRX) is sold short, with 6.1 days to cover, per published market data (October 16, 2026 intraday). FINRA data for September 30, 2026 recorded 157,938,412 shares short, 31.60% of float, down 11.63% from September 15.
- 87% of evaluable patients (13 of 15) in the REC-4881 Phase 1b/2 study had polyp burden reductions at week 12, with a median reduction of 47%, per the company business update in the 8-K dated October 15, 2026.
- USD 561 million was cash at September 30, 2026, a preliminary unaudited figure. Recursion (NASDAQ:RXRX) says runway extends into 2029 including the offering. Sanofi's option on a first candidate triggered a USD 10 million milestone.
Price Action and the Offering
Recursion reported the Sanofi option and REC-4881 data and priced stock at USD 3.25 on October 15, with a one-day rally reported, then fell on October 16. Back-solving the USD 3.82 quote and the 8.18% decline implies an October 15 close of USD 4.16, own arithmetic, so the offering price is 21.9% below that close. The order of the pricing and the rally within the session is not established in the filings reviewed. The 61.54 million new shares add 11.5% to the 535.34 million outstanding, own arithmetic, and underwriters include Leerink Partners, Goldman Sachs, Morgan Stanley and Evercore.
Clinical and Partnership Evidence
REC-4881 treats familial adenomatous polyposis at 4 mg once daily, with a data cutoff of September 10, 2026. At week 25, 12 weeks off treatment, 85% (11 of 13) remained below baseline. Grade 3 treatment-related events occurred in 4 of 26 patients, and 4 discontinued because of adverse events. The study is small, and registrational trial plans await FDA discussions, with a start targeted for the second half of 2027. Sanofi has funded and will lead an immunology candidate, and total upfront and milestone payments to date are USD 144 million, per the company.
Short Interest, Squeeze Mechanics and Risks
Shorts hold 157.94 million shares worth USD 603 million at USD 3.82, own arithmetic. Offerings change the picture in two ways: arbitrageurs who shorted ahead of pricing receive shares to close positions, which can lower reported short interest, and new supply caps rallies. That is a structural explanation, not a disclosed fact. Second quarter revenue of USD 7.67 million missed the USD 10.97 million estimate. A director sold 25,000 shares on October 8, 2026. More REC-4881 data are due on November 2, 2026, and earnings are estimated for November 4, 2026.
Where Things Stand
Recursion (NASDAQ:RXRX) fell 8.18% as the market absorbed 61.54 million new shares priced at USD 3.25, and no clinical negative was identified in the data reviewed. Short interest of 29.50% remains a fuel source, but the offering extends runway into 2029, which reduces the financing risk shorts had priced and weakens the squeeze case. Covering is more probable on catalysts such as the November 2 data than on dilution days. Evidence is balanced: small but encouraging data and USD 561 million of cash, against USD 7.67 million of quarterly revenue.






Please wait processing your request...